What is the future of inhaled antibiotics for bronchiectasis?

Emma D. Johnson; James D. Chalmers

doi:10.1080/17476348.2024.2423825

What is the future of inhaled antibiotics for bronchiectasis?

Emma D. Johnson
, James D. Chalmers (Lead / Corresponding author)

MED Respiratory Medicine and Gastroenterology

Research output: Contribution to journal › Editorial › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	907-912
Number of pages	6
Journal	Expert Review of Respiratory Medicine
Volume	18
Issue number	12
DOIs	https://doi.org/10.1080/17476348.2024.2423825
Publication status	Published - 3 Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bronchiectasis
Clinical trials
Endotypes
Exacerbations
Inhaled antibiotics

ASJC Scopus subject areas

Immunology and Allergy
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health

Access to Document

10.1080/17476348.2024.2423825

Cite this

@article{9aec0738ee454a47b28c6710836692e1,

title = "What is the future of inhaled antibiotics for bronchiectasis?",

keywords = "Bronchiectasis, Clinical trials, Endotypes, Exacerbations, Inhaled antibiotics",

author = "Johnson, \{Emma D.\} and Chalmers, \{James D.\}",

note = "{\textcopyright} 2024 Informa UK Limited, trading as Taylor \& Francis Group",

year = "2024",

month = nov,

day = "3",

doi = "10.1080/17476348.2024.2423825",

language = "English",

volume = "18",

pages = "907--912",

journal = "Expert Review of Respiratory Medicine",

issn = "1747-6348",